Type 1 fimbriae are proteinaceous surface appendages that carry adhesins specific for mannosylated glycoproteins. These fimbriae are found on most members of the familyEnterobacteriaceaeand are known to facilitate binding to a variety of eukaryotic cells, including those found on the mucosal surfaces of the alimentary tract. We have shown that the regulation of type 1 fimbrial expression inSalmonella entericaserovar Typhimurium is controlled, in part, by the products of four genes found within thefimgene cluster:fimZ,fimY,fimW, andfimU. To better understand the specific role of FimW in fimbrial expression, a mutation was constructed in this gene by the insertion of a kanamycin resistance DNA cassette into the chromosome. The resultingfimWmutation was characterized by mannose-sensitive hemagglutination and agglutination with fimbria-specific antiserum. Assays suggested that this mutant was more strongly fimbriate than the parental strain, exhibiting a four- to eightfold increase in fimbrial production. ThefimWmutation was introduced into a second strain ofSalmonella entericaserovar Typhimurium, and this mutant was also found to be strongly fimbriate compared to the parental strain. Consistent with the role of this protein as a negative regulator,fimA-lacZexpression in serovar Typhimurium, as well as inEscherichia coli, was increased twofold in the absence of functional FimW. Primer extension analysis determined thatfimWtranscription is initiated from its own promoter 31 bp upstream of the translation start site. Analysis using afimW-lacZreporter indicated thatfimWexpression in serovar Typhimurium was increased under conditions that select for poorly fimbriate bacteria and lowfimAexpression. FimW also appears to act as an autoregulator, since expression from thefimW-lacZreporter was increased in afimWmutant. FimW was partially purified by fusion with theE. colimaltose-binding protein. Use of this FimW protein extract, as well as others, in DNA-binding assays was unable to identify a specific binding site for FimW in thefimA,fimZ,fimY, orfimWpromoter regions. To analyze protein-protein interactions, FimW was expressed in a LexA-based two-hybrid system inE. coli. A significant interaction between FimW and the DNA-binding activator protein, FimZ, was detected using this system. These results indicate that FimW is a negative regulator of serovar Typhimurium type 1 fimbrial expression and may function by interfering with FimZ-mediated activation offimAexpression.

Type 1 fimbriae of Salmonella enterica serovar Typhimurium are surface appendages that carry adhesins specific for mannosylated host glycoconjugates. Regulation of the major fimbrial subunit is thought to be controlled by a number of ancillary fim genes, including fimZ , fimY , fimW , and fimU . Previous studies using a FimZ mutant have indicated that this protein is necessary for fimA expression, and in vitro DNA binding assays determined that FimZ is a transcriptional activator that binds directly to the fimA promoter. To determine the role of FimY as a potential regulator of fimbrial expression, a fimY mutant of serovar Typhimurium was generated by allelic exchange. This mutant was found to be phenotypically nonfimbriate. No transcription from the fimA promoter was detected in a fimY mutant containing a fimA-lacZ reporter construct located on the chromosome. In addition, transcription from the cloned fimY promoter was not detected in Escherichia coli unless both FimZ and FimY were present, indicating that these proteins also act as coactivators of fimY expression. Consistent with these results, there is no transcription from a fimY-lacZ reporter construct within a serovar Typhimurium fimY or fimZ mutant. Studies using the fimY-lacZ construct reveal that expression of this gene varies with environmental conditions in a manner similar to fimA expression. Extensive in vitro DNA binding assays using extracts from E. coli that overexpress FimY, as well as partially purified FimY, were unable to identify a specific interaction between FimY and the fimA or fimY promoter. The results indicate that FimY is a positive regulator of fimbrial expression and that this protein acts in cooperation with FimZ to regulate the expression of Salmonella type 1 fimbrial appendages.

Expression of type 1 fimbriae in Salmonella enterica serovar Typhimurium undergoes phase variation or alteration between a fimbriate and a non‐fimbriate phenotype. This variation is known to be dependent upon environmental conditions in vitro and is thought to be a complex process involving regulation by a number of proteins. The regulatory genes located within the fim cluster include fimZ, fimY and fimW. A fourth gene of the cluster, fimU, encodes a tRNA molecule specific for rare arginine codons. We have shown previously that fimU affects the expression of S. typhimurium type 1 fimbriae, and that fimU is functionally related to the Escherichia coli gene argU. A high frequency of rare arginine codons was found within the three fim regulatory genes, and five of these codons were clustered within fimY alone. To investigate the affects of fimU on FimY production, a FimY fusion with the E. coli maltose‐binding protein was constructed and expressed in an E. coli argU background. Western blots of extracts from the argU mutant and parental strain indicated that production of FimY was significantly reduced in the absence of a functional tRNA^Arg(UCU). FimY production in this mutant could be restored to high levels when fimU was introduced on a plasmid, and also when three rare arginine codons, located within the first 14 positions within fimY, were exchanged for major arginine codons. A Tn10 insertion from a Salmonella enteritidis fimU mutant was transduced into S. typhimurium, and this strain was analysed for the expression of type 1 fimbriae. The resulting S. typhimurium fimU mutant was found to be non‐fimbriate under all conditions tested and could be complemented by the introduction of fimU alone on a plasmid. In addition, this mutant could be complemented by transformation with fimY altered in the first three rare arginine codons. Reverse transcriptase–polymerase chain reaction confirmed that the fimY transcript was present at similar levels in the fimU mutant and parental strain. These results indicated that the observed inhibition of protein expression was not occurring at the transcriptional level. Analysis of expression of the malEfimY fusion in the S. typhimurium fimU mutant and parental strain confirmed the data observed in E. coli. In contrast, a FimW fusion was found to be produced at similar levels in both the fimU mutant and the parental strain. Together, these data indicate that the absence of a functional fimU results in the inhibition of efficient FimY translation, and thus type 1 fimbrial production in S. typhimurium.

Cholera toxin (CT) and relatedEscherichia colienterotoxins LTI and LTIIb have a conserved hydrophobic region at the AB₅interface postulated to be important for toxin assembly. Hydrophobic residue F223 in the A subunit of CT (CTA) as well as residues 174, L77, and T78 in the B subunit of CT (CTB) were replaced individually with aspartic acid, and the resulting CTA and CTB variants were analyzed for their ability to assemble into holotoxin in vivo. CTA-F223D holotoxin exhibited decreased stability and toxicity and increased susceptibility to proteolysis by trypsin. CTB-L77D was unable to form functional pentamers. CTB-I74D and CTB-T78D formed pentamers that bound to GM₁andd-galactose but failed to assemble with CTA to form holotoxin. In contrast, CTB-T78D and CTA-F223H interacted with each other to form a significant amount of holotoxin in vivo. Our findings support the importance of hydrophobic interactions between CTA and CTB in holotoxin assembly. We also developed an efficient method for assembly of CT in vitro, and we showed that CT assembled in vitro was comparable to wild-type CT in toxicity and antigenicity. CTB-I74D and CTB-T78D did not form pentamers or holotoxin in vitro, and CTA-F223D did not form holotoxin in vitro. The efficient system for in vitro assembly of CT described here should be useful for future studies on the development of drugs to inhibit CT assembly as well as the development of chimeric CT-like molecules as potential vaccine candidates.